This study looks at how well a new medicine called toripalimab works with chemotherapy for people with nasopharyngeal cancer that has come back or spread. Nasopharyngeal cancer affects the area behind the nose and throat. The study uses two chemotherapy drugs: cisplatin and gemcitabine. The main goal is to see how many people respond to this treatment by measuring the size of their tumors with special guidelines (RECIST v1.1). To join, participants need to have a specific type of cancer confirmed by tests and have already tried other treatments without success. They should not have cancer that could be treated with local therapy aimed to cure it, or have had other treatments for their spreading cancer recently. Also, they should not have severe symptoms like uncontrolled pain or untreated cancer in the brain.
- Participants need to visit the study center for check-ups and treatment.
- There might be risks and side effects from the treatment.
- Participants may receive compensation for their time and travel.